Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

A 12-month, Open-label, Prospective, Multicenter, Interventional, Single-arm Study Assessing the Efficacy and Safety of Ofatumumab 20 mg Subcutaneous (s.c.) Injection in Relapsing Multiple Sclerosis (RMS) Patients in China

ClinicalTrials.gov Identifier: NCT05199571

Novartis Reference Number: COMB157G2402

Last Update: Sep 26, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The purpose of this study is to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.

Condition 
Relapsing Multiple Sclerosis
Phase 
Phase 4
Overall status 
Recruiting
Start date 
Jul 22, 2022
Completion date 
Oct 30, 2026
Gender 
All
Age(s)
18 Years - 55 Years (Adult)

Interventions

Biological
Ofatumumab
Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab

Eligibility Criteria

Inclusion Criteria:

Male or female Chinese aged 18-55 years (inclusive) at their enrollment of the study (signing the study consent form).

Clinical definite diagnosis of RMS according to the 2017 Revised McDonald criteria (Thompson et al 2018, and the documentation prior to their enrollment to the study (signing the study consent form) of:

Two documented relapses during the past 2 years, or
One documented relapse during the last year, or
A positive Gd-enhancing MRI scan during the year prior to Screening. Note: Screening MRI scan may be used if no positive Gd-enhancing scan exists from prior year.
Disability status with an EDSS score of 0 - 5.5 (inclusive) at Screening.
Neurologically stable within 1 month prior to both Screening and Baseline (including no MS relapse in this period).

Exclusion Criteria:

Participants with primary progressive MS (PPMS) or secondary progressive MS (SPMS) without disease activity
Participants meeting criteria for neuromyelitis optica spectrum disorder (NMOSD)
Pregnant or nursing (lactating) women
Women of child-bearing potential unless using effective methods of contraception while taking study treatment and for at least 6 months after stopping medication
Participants with an active chronic disease of the immune system other than MS
Participants with neurological findings consistent with PML or confirmed PML
Participants with active hepatitis B disease
Participants with active systemic infections (including but not limited to active COVID-19 infection) or known to have AIDS or to test positive for HIV antibody at Screening
Participants at high risk of developing or having reactivation of syphilis or tuberculosis
Have received any live or live-attenuated vaccines within four weeks prior to first study drug administration
Have been treated with medications as specified or within timeframes specified in the protocol
Any other disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the participants to cooperate and comply with the study procedures.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Locations

China
Novartis Investigative Site
Recruiting
Lanzhou, 730030
Gansu
China
Novartis Investigative Site
Recruiting
Shijiazhuang, 050000
Hebei
China
Novartis Investigative Site
Recruiting
Harbin, 150001
Heilongjiang
China
Novartis Investigative Site
Recruiting
Suzhou, 215004
Jiangsu
China
Novartis Investigative Site
Recruiting
Hangzhou, 310006
Zhejiang
China
Novartis Investigative Site
Recruiting
Guang Zhou, 510080
-
China
Novartis Investigative Site
Recruiting
Guang Zhou, 510260
-
China
Novartis Investigative Site
Recruiting
Shanghai, 200025
-
China
Novartis Investigative Site
Recruiting
Tianjin, 300052
-
China

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]